ICON, the international contract research organisation (CRO) based in Ireland, has relocated its central laboratory in Singapore to new, larger premises to accommodate a surge in demand for its services.

The new facility in the eastern part of the city state is ICON’s response to a 149% rise in demand for its central laboratory services in Singapore over the last six months, the CRO said.

The move also enables ICON to expand its test menu in the region to take in increased esoteric testing as well as flow cytometry, molecular diagnostics and biomarkers, complementing the services of the CRO’s other wholly owned central laboratories in Europe, India and the United States.

Noting that the company is now in its 10th year of operation there, Bob Scott-Edwards, president, ICON Central Laboratories, commented: “Singapore has become a regional hub for drug development in Asia-Pacific and we now have the capacity, the range of testing services and, above all, a highly experienced team of lab professionals to support the growth of clinical trials in the region.”

ICON Central Laboratories Singapore supports all the major therapeutic areas, including cardiovascular, oncology, endocrinology/metabolism and virology. It serves as a regional hub for test samples from Australia, New Zealand, South Korea, Malaysia, Singapore, Taiwan, Japan, Thailand, Hong Kong, China and Indonesia.

In March the Singapore facility secured accreditation from the College of American Pathologists (CAP).